Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Company Information
About this company
Key people
Michael Donald Dale
President, Chief Executive Officer, Director
Lindsey Hartley
Chief Financial Officer
Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Jens Schroeder Kemp
Chief Marketing Officer
Rick Ditto
Vice President - Global Health Economics, Reimbursement & Policy
Erick Wayne Devinney
Chief Innovation Officer
Paul G. Thomas
Independent Chairman of the Board
Amy A. Mcbride-Wendell
Lead Independent Director
William P. Burke
Independent Director
John H. Johnson
Independent Director
Alan M. Levine
Independent Director
Click to see more
Key facts
- Shares in issue50.12m
- EPICAXGN
- ISINUS05463X1063
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$1.72bn
- Employees451
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.